SRDX remains a great growth play in the convergence of medical devices and surface coatings. The pipeline is outstanding. Non DES growth continues to churn along, which is often overlooked and as the MDT deal proves, there is more than one way to participate in the DES arena.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.